An overview of inflammatory breast cancer
Keywords:Inflammatory, Breast, Cancer, Disease
Inflammatory breast cancer is an uncommon and severe malignancy that frequently goes undiagnosed at first because it presents similarly to more benign breast diseases like mastitis, resulting in delayed treatment. Inflammatory breast cancer affects 1% to 5% of all occurrences of breast cancer and accounts for 8% to 10% of all breast cancer-related deaths. Erythema, skin abnormalities, nipple inversion, edema, and warmth of the affected breast are all signs of inflammatory breast cancer. Recognized risk factors for inflammatory breast cancer include young age at the time of diagnosis, obesity and African American ethnicity. Rapid onset within 3 months and pathologic evidence of invasive carcinoma leads to diagnosis of disease further including erythema occupying at least one-third of the breast, tumour may or may not be present in this case. Chemotherapy, surgery, and radiation make up the trimodal therapy used to treat inflammatory breast cancer. A modified radical mastectomy performed as part of an aggressive surgical strategy improves survival rates. Although patients with inflammatory breast cancer have worse outcomes than those with noninflammatory breast cancer, those who complete trimodal therapy have a positive locoregional control rate, highlighting the significance of an early diagnosis. Physicians must be aware and examine any clinical manifestation of inflammatory breast cancer if present to make a prompt diagnosis and refer patient for expert care timely also awareness and cancer screening can help in prevention of disease. The purpose of this research is to review the available information about an overview of inflammatory breast cancer.
Sobin LH, Compton CC. TNM seventh edition: What's new, what's changed. Cancer. 2010;116(22):5336-9.
Hester RH, Hortobagyi GN, Lim B. Inflammatory breast cancer: early recognition and diagnosis is critical. Am J Obstet Gynecol. 2021;225(4):392-6.
Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, et al. Inflammatory breast cancer: what we know and what we need to learn. The Oncologist. 2012;17(7):891-9.
Chainitikun S, Saleem S, Lim B, Valero V, Ueno NT. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res. 2021;29:1-12.
Dawood S, Ueno NT, Cristofanilli M. The medical treatment of inflammatory breast cancer. Semin Oncol. 2008;35(1):64-71.
Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010;60(6):351-75.
Tarantino P, Niman SM, Erick TK, Priedigkeit N, Harrison BT, Giordano A, et al. HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications. Eur J Cancer. 2022;174:277-86.
Giordano SH, Hortobagyi GN. Inflammatory breast cancer: clinical progress and the main problems that must be addressed. Breast Cancer Res. 2003;5(6):284-8.
Molckovsky A, Fitzgerald B, Freedman O, Heisey R, Clemons M. Approach to inflammatory breast cancer. Can Fam Physician. 2009;55(1):25-31.
Singletary SE, Cristofanilli M. Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol. 2008;35(1):7-10.
Jagsi R, Mason G, Overmoyer BA, Woodward WA, Badve S, Schneider RJ, et al. Komen-IBCRF IBC Collaborative in partnership with the Milburn Foundation. Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. Breast Cancer Res Treat. 2022;192(2):235-43.
Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2000;2(6):423-9.
Yaghoobi R, Talaizade A, Lal K, Ranjbari N, Sohrabiaan N, Feily A. Inflammatory Breast Carcinoma Presenting with Two Different Patterns of Cutaneous Metastases: Carcinoma Telangiectaticum and Carcinoma Erysipeloides. J Clin Aesth Dermatol. 2015;8(8):47-51.
Mele M, Sørensen AS, Bruun J, Funder JA, Tramm T, Bodilsen A, et al. Inflammatory breast cancer: A review from our experience. Breast Dis. 2019;38(2):47-55.
Vallone MG, Casas JG, González VM, Larralde M. Dermoscopy of inflammatory breast cancer. Anais Brasileiros de Dermatologia. 2018;93(2):289-90.
Mamouch F, Berrada N, Aoullay Z, El Khanoussi B, Errihani H. Inflammatory Breast Cancer: A Literature Review. World J Oncol. 2018;9(5-6):129-35.
Wecsler JS, Tereffe W, Pedersen RC, Sieffert MR, Mack WJ, Cui H, et al. Lymph node status in inflammatory breast cancer. Breast Cancer Res Treatment. 2015;151(1):113-20.
Alunni JP. Imaging inflammatory breast cancer. Diagnostic and interventional imaging. 2012;93(2):95-103.
Cristofanilli M, Buzdar AU, Hortobágyi GN. Update on the management of inflammatory breast cancer. The Oncologist. 2003;8(2):141-8.
Singletary SE. Surgical management of inflammatory breast cancer. Semin Oncol. 2008;35(1):72-7.
Liu SV, Melstrom L, Yao K, Russell CA, Sener SF. Neoadjuvant therapy for breast cancer. J Surg Oncol. 2010;101(4):283-91.
Bristol IJ, Buchholz TA. Inflammatory breast cancer: current concepts in local management. Breast Dis. 2005;22:75-83.
Chainitikun S, Espinosa Fernandez JR, Long JP. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PloS One. 2021;16(4):e0250057.